| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 33 | 2024 | 4993 | 3.020 |
Why?
|
| Neurosurgical Procedures | 6 | 2021 | 634 | 1.420 |
Why?
|
| Glioma | 14 | 2022 | 1988 | 1.410 |
Why?
|
| Glioblastoma | 11 | 2022 | 1781 | 1.310 |
Why?
|
| Meningeal Neoplasms | 6 | 2022 | 473 | 1.250 |
Why?
|
| Melanoma | 11 | 2024 | 5591 | 0.840 |
Why?
|
| Brain Mapping | 6 | 2024 | 638 | 0.810 |
Why?
|
| Cerebral Ventricle Neoplasms | 2 | 2023 | 78 | 0.760 |
Why?
|
| Language | 4 | 2024 | 327 | 0.700 |
Why?
|
| STAT3 Transcription Factor | 6 | 2022 | 1146 | 0.650 |
Why?
|
| Fourth Ventricle | 2 | 2023 | 50 | 0.630 |
Why?
|
| Astrocytes | 2 | 2020 | 405 | 0.620 |
Why?
|
| Gene Fusion | 1 | 2018 | 214 | 0.560 |
Why?
|
| Astrocytoma | 1 | 2018 | 335 | 0.510 |
Why?
|
| Cerebral Cortex | 2 | 2019 | 634 | 0.480 |
Why?
|
| Xanthogranuloma, Juvenile | 1 | 2014 | 39 | 0.480 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2024 | 7929 | 0.460 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2018 | 520 | 0.450 |
Why?
|
| Dacarbazine | 1 | 2016 | 505 | 0.440 |
Why?
|
| Cytomegalovirus | 1 | 2016 | 493 | 0.420 |
Why?
|
| Cerebrospinal Fluid Shunts | 2 | 2017 | 89 | 0.420 |
Why?
|
| Pituitary Neoplasms | 1 | 2014 | 218 | 0.420 |
Why?
|
| Immunotherapy | 5 | 2023 | 3539 | 0.410 |
Why?
|
| Tumor Microenvironment | 4 | 2022 | 2999 | 0.400 |
Why?
|
| Disease Management | 1 | 2017 | 1111 | 0.400 |
Why?
|
| Cytomegalovirus Infections | 1 | 2016 | 485 | 0.390 |
Why?
|
| Pinealoma | 2 | 2022 | 52 | 0.380 |
Why?
|
| Radiosurgery | 4 | 2024 | 1368 | 0.380 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2009 | 101 | 0.350 |
Why?
|
| Dura Mater | 1 | 2010 | 77 | 0.340 |
Why?
|
| Vasospasm, Intracranial | 1 | 2009 | 24 | 0.340 |
Why?
|
| Cerebral Angiography | 1 | 2009 | 148 | 0.320 |
Why?
|
| Humans | 56 | 2024 | 271636 | 0.310 |
Why?
|
| Oncolytic Virotherapy | 2 | 2012 | 235 | 0.310 |
Why?
|
| Aging | 1 | 2016 | 1578 | 0.310 |
Why?
|
| Intracranial Aneurysm | 1 | 2009 | 129 | 0.310 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 5328 | 0.300 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2007 | 65 | 0.300 |
Why?
|
| Pregnatrienes | 1 | 2007 | 2 | 0.290 |
Why?
|
| Cerebral Infarction | 1 | 2007 | 72 | 0.280 |
Why?
|
| Aggression | 1 | 2009 | 253 | 0.280 |
Why?
|
| Personality Disorders | 1 | 2009 | 163 | 0.280 |
Why?
|
| Catheterization | 1 | 2009 | 424 | 0.280 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2010 | 331 | 0.280 |
Why?
|
| Hydrocephalus | 2 | 2021 | 260 | 0.280 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2007 | 181 | 0.280 |
Why?
|
| Adult | 27 | 2024 | 81791 | 0.270 |
Why?
|
| Health Status | 2 | 2009 | 633 | 0.270 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 1013 | 0.250 |
Why?
|
| Retrospective Studies | 17 | 2024 | 39731 | 0.240 |
Why?
|
| Pathology | 1 | 2005 | 108 | 0.230 |
Why?
|
| Neurosurgery | 1 | 2005 | 117 | 0.230 |
Why?
|
| Blood-Brain Barrier | 2 | 2020 | 249 | 0.230 |
Why?
|
| Glioma, Subependymal | 1 | 2023 | 24 | 0.220 |
Why?
|
| Cohort Studies | 7 | 2020 | 9467 | 0.220 |
Why?
|
| Male | 28 | 2024 | 128836 | 0.220 |
Why?
|
| Neurology | 1 | 2005 | 119 | 0.220 |
Why?
|
| Aged | 19 | 2024 | 73421 | 0.220 |
Why?
|
| Stem Cells | 1 | 2010 | 1231 | 0.220 |
Why?
|
| Genetic Therapy | 2 | 2012 | 1732 | 0.220 |
Why?
|
| Brain Injuries | 1 | 2009 | 799 | 0.210 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 662 | 0.210 |
Why?
|
| Mutation | 3 | 2018 | 15913 | 0.210 |
Why?
|
| Female | 27 | 2024 | 148992 | 0.210 |
Why?
|
| Middle Aged | 22 | 2024 | 90349 | 0.210 |
Why?
|
| Meningioma | 2 | 2020 | 307 | 0.190 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2020 | 550 | 0.190 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2021 | 33 | 0.190 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2021 | 31 | 0.190 |
Why?
|
| Ocular Motility Disorders | 1 | 2021 | 43 | 0.190 |
Why?
|
| Combined Modality Therapy | 6 | 2022 | 9042 | 0.180 |
Why?
|
| Adolescent | 9 | 2023 | 32609 | 0.170 |
Why?
|
| Risk Assessment | 3 | 2020 | 6876 | 0.170 |
Why?
|
| Prognosis | 6 | 2023 | 22525 | 0.160 |
Why?
|
| Connectome | 1 | 2021 | 114 | 0.160 |
Why?
|
| Biomarkers, Tumor | 3 | 2019 | 10743 | 0.160 |
Why?
|
| Young Adult | 9 | 2024 | 22094 | 0.160 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 595 | 0.160 |
Why?
|
| Signal Transduction | 3 | 2015 | 12219 | 0.150 |
Why?
|
| Treatment Outcome | 11 | 2024 | 33846 | 0.150 |
Why?
|
| Oligodendroglioma | 1 | 2018 | 106 | 0.150 |
Why?
|
| Convection | 2 | 2007 | 6 | 0.150 |
Why?
|
| Cranial Nerve Injuries | 1 | 2017 | 9 | 0.150 |
Why?
|
| Ventriculostomy | 1 | 2017 | 42 | 0.140 |
Why?
|
| Animals | 13 | 2020 | 62757 | 0.140 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2017 | 52 | 0.140 |
Why?
|
| Speech Disorders | 1 | 2017 | 85 | 0.140 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 31032 | 0.130 |
Why?
|
| Cell Lineage | 1 | 2018 | 706 | 0.120 |
Why?
|
| ErbB Receptors | 2 | 2016 | 2383 | 0.120 |
Why?
|
| Cognition | 1 | 2021 | 980 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 10354 | 0.120 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 5113 | 0.120 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 2 | 2013 | 211 | 0.120 |
Why?
|
| Child | 5 | 2020 | 30401 | 0.110 |
Why?
|
| Postoperative Care | 1 | 2017 | 731 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 7788 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 15254 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2019 | 3924 | 0.100 |
Why?
|
| Gene Expression | 2 | 2018 | 3688 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 522 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2014 | 835 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2012 | 77 | 0.100 |
Why?
|
| Brain | 3 | 2024 | 4251 | 0.100 |
Why?
|
| Risk Factors | 5 | 2020 | 18016 | 0.100 |
Why?
|
| Tumor Escape | 2 | 2013 | 248 | 0.100 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2013 | 208 | 0.100 |
Why?
|
| Cancer Vaccines | 1 | 2017 | 751 | 0.090 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 2365 | 0.090 |
Why?
|
| Macrophages | 3 | 2022 | 1376 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 207 | 0.090 |
Why?
|
| Radiation Injuries | 1 | 2017 | 1472 | 0.090 |
Why?
|
| Age Factors | 2 | 2016 | 5509 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 3363 | 0.090 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 12008 | 0.090 |
Why?
|
| Neural Stem Cells | 1 | 2011 | 184 | 0.090 |
Why?
|
| Skin Neoplasms | 2 | 2020 | 4888 | 0.080 |
Why?
|
| Boronic Acids | 1 | 2011 | 355 | 0.080 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2009 | 78 | 0.080 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2009 | 39 | 0.080 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2011 | 295 | 0.080 |
Why?
|
| Collagen | 1 | 2012 | 737 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 609 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 1444 | 0.080 |
Why?
|
| Pyrazines | 1 | 2011 | 513 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2016 | 1206 | 0.080 |
Why?
|
| Genetic Vectors | 2 | 2012 | 1883 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2019 | 9093 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 2 | 2012 | 1599 | 0.080 |
Why?
|
| Demography | 1 | 2009 | 435 | 0.070 |
Why?
|
| Spinal Diseases | 1 | 2008 | 131 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 16606 | 0.070 |
Why?
|
| Infusions, Intralesional | 1 | 2007 | 7 | 0.070 |
Why?
|
| Survival Rate | 2 | 2019 | 12530 | 0.070 |
Why?
|
| Lumbar Vertebrae | 1 | 2008 | 249 | 0.070 |
Why?
|
| Placebo Effect | 1 | 2007 | 37 | 0.070 |
Why?
|
| Transferrin | 1 | 2007 | 75 | 0.070 |
Why?
|
| Spinal Fusion | 1 | 2008 | 150 | 0.070 |
Why?
|
| Exotoxins | 1 | 2007 | 76 | 0.070 |
Why?
|
| Mice, Nude | 4 | 2019 | 4358 | 0.070 |
Why?
|
| Adenoviridae | 1 | 2012 | 1510 | 0.070 |
Why?
|
| Interleukin-13 | 1 | 2007 | 130 | 0.070 |
Why?
|
| Equipment Failure | 1 | 2007 | 198 | 0.070 |
Why?
|
| Interleukin-4 | 1 | 2007 | 291 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2016 | 2759 | 0.070 |
Why?
|
| Factor Analysis, Statistical | 1 | 2007 | 354 | 0.070 |
Why?
|
| Internationality | 1 | 2007 | 206 | 0.070 |
Why?
|
| Bacterial Toxins | 1 | 2007 | 229 | 0.060 |
Why?
|
| Neuroanatomy | 1 | 2005 | 13 | 0.060 |
Why?
|
| Ipilimumab | 2 | 2023 | 759 | 0.060 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2008 | 508 | 0.060 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2006 | 53 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2007 | 218 | 0.060 |
Why?
|
| Decompression, Surgical | 1 | 2006 | 147 | 0.060 |
Why?
|
| Pseudotumor Cerebri | 1 | 2006 | 64 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 1264 | 0.060 |
Why?
|
| Atlases as Topic | 1 | 2024 | 46 | 0.060 |
Why?
|
| Prosthesis-Related Infections | 1 | 2007 | 229 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 6208 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2007 | 14653 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2024 | 1432 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 1424 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 3670 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 7463 | 0.060 |
Why?
|
| Incidence | 2 | 2020 | 5856 | 0.060 |
Why?
|
| Neoplasms | 1 | 2010 | 15903 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 3852 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2007 | 2334 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2005 | 549 | 0.050 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 1827 | 0.050 |
Why?
|
| CD11c Antigen | 1 | 2021 | 57 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2017 | 5688 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2005 | 690 | 0.050 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2021 | 147 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 1666 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 1338 | 0.050 |
Why?
|
| Pupil Disorders | 1 | 2021 | 23 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2007 | 2619 | 0.050 |
Why?
|
| Nystagmus, Pathologic | 1 | 2021 | 25 | 0.050 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2012 | 170 | 0.050 |
Why?
|
| Tissue Array Analysis | 2 | 2013 | 759 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 3934 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 4352 | 0.040 |
Why?
|
| Comorbidity | 1 | 2007 | 2435 | 0.040 |
Why?
|
| Mice | 7 | 2019 | 36006 | 0.040 |
Why?
|
| Melanocytes | 1 | 2021 | 241 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 4890 | 0.040 |
Why?
|
| Executive Function | 1 | 2021 | 149 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2013 | 2912 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 7222 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2022 | 457 | 0.040 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2021 | 153 | 0.040 |
Why?
|
| Australia | 1 | 2020 | 261 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2020 | 349 | 0.040 |
Why?
|
| Metabolic Flux Analysis | 1 | 2019 | 27 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 5195 | 0.040 |
Why?
|
| Craniotomy | 1 | 2021 | 306 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2019 | 5804 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 4391 | 0.040 |
Why?
|
| Rats | 1 | 2007 | 6633 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 2022 | 515 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2024 | 1550 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 2013 | 1566 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2024 | 2035 | 0.040 |
Why?
|
| Nerve Net | 1 | 2021 | 271 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2021 | 911 | 0.040 |
Why?
|
| United States | 3 | 2022 | 16036 | 0.040 |
Why?
|
| Lateral Ventricles | 1 | 2017 | 26 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 267 | 0.040 |
Why?
|
| Memory | 1 | 2021 | 441 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 775 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2021 | 1436 | 0.030 |
Why?
|
| Cell Line, Tumor | 4 | 2013 | 14868 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2007 | 9323 | 0.030 |
Why?
|
| Metabolome | 1 | 2019 | 356 | 0.030 |
Why?
|
| Necrosis | 1 | 2017 | 604 | 0.030 |
Why?
|
| Obesity | 1 | 2008 | 2952 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 679 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2021 | 1110 | 0.030 |
Why?
|
| Cell Proliferation | 3 | 2013 | 7292 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 1248 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 6266 | 0.030 |
Why?
|
| Oxyquinoline | 1 | 2013 | 6 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 592 | 0.030 |
Why?
|
| Disease Progression | 2 | 2017 | 6905 | 0.030 |
Why?
|
| Cell Tracking | 1 | 2013 | 38 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 135 | 0.030 |
Why?
|
| Time Factors | 1 | 2007 | 13116 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2012 | 4984 | 0.030 |
Why?
|
| Polylysine | 1 | 2012 | 19 | 0.030 |
Why?
|
| Gamma Rays | 1 | 2013 | 241 | 0.030 |
Why?
|
| Organometallic Compounds | 1 | 2013 | 209 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2012 | 92 | 0.030 |
Why?
|
| Injections, Intralesional | 1 | 2012 | 166 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 339 | 0.020 |
Why?
|
| Chickens | 1 | 2012 | 791 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2012 | 202 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 2365 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2012 | 261 | 0.020 |
Why?
|
| SEER Program | 1 | 2015 | 1046 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 13989 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2011 | 320 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2013 | 431 | 0.020 |
Why?
|
| Proteolysis | 1 | 2012 | 379 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 718 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 1142 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 2270 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 1965 | 0.020 |
Why?
|
| Bortezomib | 1 | 2011 | 542 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 4998 | 0.020 |
Why?
|
| RNA Interference | 1 | 2013 | 1397 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 2298 | 0.020 |
Why?
|
| Virus Replication | 1 | 2012 | 761 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 3391 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2010 | 631 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 1212 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2012 | 1396 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 815 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 2468 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2008 | 242 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 1468 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 5180 | 0.020 |
Why?
|
| Base Sequence | 1 | 2013 | 5499 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 3646 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 2218 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 3651 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2012 | 1669 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2021 | 13385 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 1588 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 2503 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 1469 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 3262 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2008 | 1017 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 4370 | 0.010 |
Why?
|
| Cytokines | 1 | 2013 | 2837 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2012 | 5779 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2010 | 3077 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2012 | 6488 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2013 | 4191 | 0.010 |
Why?
|
| Phenotype | 1 | 2013 | 6510 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2008 | 2287 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 7817 | 0.010 |
Why?
|
| Apoptosis | 1 | 2012 | 7834 | 0.010 |
Why?
|
| Recurrence | 1 | 2006 | 4884 | 0.010 |
Why?
|
| Quality of Life | 1 | 2008 | 4745 | 0.010 |
Why?
|